Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

ACR Convergence 2021

ACR Convergence 2021

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with RA at high CV risk, show the ORAL Surveillance results.

ACR Convergence 2021

Olokizumab benefits extend to patients with RA refractory to methotrexate or TNF inhibitors

Olokizumab shows clinical and physical benefits for patients with rheumatoid arthritis (RA) with inadequate responses to methotrexate and tumor necrosis inhibitor (TNF) inhibitor therapy in the latest CREDO findings. Read now

ACR Convergence 2021

Add-on treatment for lupus nephritis: Should belimumab or voclosporin be used first?

In “The Great Debate”, experts discussed which new add-on treatment option should be used first for patients with active lupus nephritis despite conventional therapy. Read now

Expert video interviews from ACR Convergence 2021

12-11-2021 | ACR 2021 | Conference coverage | Video

Olokizumab: What makes it an effective and novel treatment for RA?

Roy Fleischmann discusses the implications of the CREDO2 and 3 trial findings looking at olokizumab efficacy versus adalimumab as an add-on to methotrexate and in TNF inhibitor non-responders.

07-11-2021 | ACR 2021 | Conference coverage | Video

Risankizumab for PsA: How will the KEEPsAKE 1 and 2 findings impact clinical practice?

Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis.

06-11-2021 | ACR 2021 | Conference coverage | Video

The ARIAA trial of abatacept for subclinical arthritis

Jürgen Rech outlines the findings from the ARIAA trial, which demonstrated benefits of abatacept in people at risk for rheumatoid arthritis, and discusses the potential role of treating subclinical inflammation to delay or prevent the onset of clinical disease.

Tofacitinib safety

10-11-2021 | ACR 2021 | Conference coverage | News

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

11-11-2021 | ACR 2021 | Conference coverage | News

Real-world study suggests no elevated CV risk with tofacitinib in overall RA population

Treatments for systemic lupus erythematosus, lupus nephritis

08-11-2021 | ACR 2021 | Conference coverage | News

Add-on treatment for lupus nephritis: Should belimumab or voclosporin be used first?

09-11-2021 | ACR 2021 | Conference coverage | News

BLISS-BELIEVE: Adding rituximab to belimumab does not improve SLE disease control

09-11-2021 | ACR 2021 | Conference coverage | News

Phase 2 trial supports further investigation of iberdomide for SLE

10-11-2021 | ACR 2021 | Conference coverage | News

​​​​​​​AURORA 2 shows enduring proteinuria benefits with voclosporin in lupus nephritis

08-11-2021 | ACR 2021 | Conference coverage | News

Lupus nephritis patients may experience declining kidney function despite proteinuria resolution

Treat-to-target strategies in gout

06-11-2021 | ACR 2021 | Conference coverage | News

Data support serum urate-based treat-to-target approach in gout

09-11-2021 | ACR 2021 | Conference coverage | News

​​​​​​​Reassurance on CV risk with treat-to-target strategies in gout

Early rheumatoid arthritis studies

06-11-2021 | ACR 2021 | Conference coverage | News

Abatacept shows potential for subclinical arthritis

06-11-2021 | ACR 2021 | Conference coverage | News

Targeting unmet needs could improve QoL in early RA

09-11-2021 | ACR 2021 | Conference coverage | News

Piclidenoson misses primary endpoint for early RA

More news from ACR Convergence 2021

12-11-2021 | ACR 2021 | Conference coverage | News

Telemedicine feasible for delivery of SLE follow-up care

11-11-2021 | ACR 2021 | Conference coverage | News

Adherence to a treat-to-target approach in RA not hindered by virtual vs face-to-face visits

10-11-2021 | ACR 2021 | Conference coverage | News

High BMI may adversely affect PsA treatment response

10-11-2021 | ACR 2021 | Conference coverage | News

Increased risk for breakthrough COVID-19 infection in vaccinated patients with AIRDs

10-11-2021 | ACR 2021 | Conference coverage | News

IL-17A inhibition demonstrates potential for giant cell arteritis

09-11-2021 | ACR 2021 | Conference coverage | News

No benefit to methotrexate use with ustekinumab in PsA

09-11-2021 | ACR 2021 | Conference coverage | News

Pirfenidone shows promise for patients with RA-ILD

09-11-2021 | ACR 2021 | Conference coverage | News

Olokizumab benefits extend to patients with RA refractory to methotrexate or TNF inhibitors

09-11-2021 | ACR 2021 | Conference coverage | News

Statins show CVD benefits in RA with only a modest risk for new-onset diabetes

09-11-2021 | ACR 2021 | Conference coverage | News

COVID-19 vaccine response factors identified in rituximab-treated patients

08-11-2021 | ACR 2021 | Conference coverage | News

Improved renal outcomes in children with lupus overshadowed by racial disparities

08-11-2021 | ACR 2021 | Conference coverage | News

Positive phase 2b results for ianalumab in primary Sjögren’s syndrome

08-11-2021 | ACR 2021 | Conference coverage | News

Research allays concerns over TNF inhibitor use in HIV-positive patients

07-11-2021 | ACR 2021 | Conference coverage | News

Tocilizumab candidate for glucocorticoid-sparing agent in polymyalgia rheumatica

07-11-2021 | ACR 2021 | Conference coverage | News

Brepocitinib shows promise in psoriatic arthritis

07-11-2021 | ACR 2021 | Conference coverage | News

Belimumab, arimoclomol disappoint in myositis trials

07-11-2021 | ACR 2021 | Conference coverage | News

US study identifies racial disparities in lupus nephritis mortality

07-11-2021 | ACR 2021 | Conference coverage | News

High rates of severe COVID-19 in patients with vasculitis, polymyalgia rheumatica

06-11-2021 | ACR 2021 | Conference coverage | News

KEEPsAKE trials show benefits of risankizumab in patients with PsA

06-11-2021 | ACR 2021 | Conference coverage | News

Observational data show patterns of neurologic, ocular manifestations in ANCA-associated vasculitis


This information is brought to you by Medicine Matters in partnership with medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology.


Image Credits